Danny Goldstein, a doctoral candidate in pharmacy in Israel, has developed a way of combining Taxol with Herceptin monoclonal antibody that overcomes the problem of the toxic emulsion normally required to make Taxol soluable. Goldstein’s nanoemulsion, used to create a Taxol-Herceptin combination and tested in mice, may allow superior, sustained delivery of this therapy to patients with advanced, mestatstic prostate cancer. Clinical trials will begin in about two years. Full story Nanotechnology Improves Chemotherapy-Antibody Combination, June 22.